A genetic outline of the pathways to cell death in Alzheimer's disease, Parkinson's disease, frontal dementias and related disorders

doi:10.1017/CBO9780511544873.018

17 - A genetic outline of the pathways to cell death in Alzheimer's disease, Parkinson's disease, frontal dementias and related disorders

from Part I - Basic aspects of neurodegeneration

Published online by Cambridge University Press: 04 August 2010

Anthony E. Lang and

M. Flint Beal: Affiliation:
Cornell University, New York
Anthony E. Lang: Affiliation:
University of Toronto
Albert C. Ludolph: Affiliation:
Universität Ulm, Germany
John Hardy: Affiliation:
Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

Book contents

Get access

Summary

Over the last 10 years, genetic and pathological analysis has allowed the dissection of the major pathways to cell death in Alzheimer's disease, Pick's disease and Lewy body disease. The central findings are these.

First, the pathology of Alzheimer's disease consists of plaques, made of the Aβ peptide, derived from the APP protein, and neurofibrillary tangles made of the tau protein: Lewy bodies, made of the synuclein protein, are a frequent, but not invariant pathology of Alzheimer's disease (Hansen & Samuel, 1997).

Second, all pathogenic mutations in the APP and presenilin genes alter APP metabolism such that more of the peptide, Aβ42, is produced (Hardy & Selkoe, 2002). These data suggest that Aβ is the primary molecule in the pathogenic cascade for Alzheimer's disease and that tau dysfunction and tangle formation are a necessary downstream event in disease pathogenesis and that α-synuclein dysfunction and Lewy body formation are an occasional downstream event in disease pathogenesis.

Third, mutations in the tau gene causes some frontal temporal dementias and other entities in which tau is deposited (Hutton et al., 1998). In some sporadic tangle disorders, the tau haplotype is a risk factor for disease (Baker et al., 1999). These data suggest that cell death and dementia are a consequence of tau dysfunction and tangle formation (Hardy et al., 1998).

Fourth, mutations in the α-synuclein gene cause Parkinson's disease and other entities in which α-synuclein is deposited (Polymeropoulos et al., 1997).

Type: Chapter
Information: Neurodegenerative Diseases
Neurobiology, Pathogenesis and Therapeutics
, pp. 222 - 226

DOI: https://doi.org/10.1017/CBO9780511544873.018 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Baker, M., Litvan, I., Houlden, H.et al. (1999). Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet., 8(4), 711–15CrossRef Google Scholar PubMed

Bales, K. R., Verina, T., Cummins, D. J.et al. (1999). Apolipoprotein E is essential for amyloid deposition in the APP (V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl Acad. Sci., USA, 96, 15233–8CrossRef Google Scholar PubMed

Bard, F., Cannon, C., Barbour, R.et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 6, 916–19CrossRef Google Scholar

Brown, J., Ashworth, A., Gydesen, S.et al. (1995). Familial non-specific dementia maps to chromosome 3. Hum. Mol. Genet., 4, 1625–8CrossRef Google Scholar PubMed

Burns, M. & Duff, K. (2003). Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease. Neurochem. Res., 28(7), 979–86CrossRef Google Scholar

Bush, A. I., Pettingell, W. H., Multhaup, G.et al. (1994). Rapid induction of Alzheimer A beta amyloid formation by zinc. Science, 265, 1464–7CrossRef Google Scholar

Cherny, R. A., Atwood, C. S., Xilinas, M. E.et al. (2001). Treatment with a copper–zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 30, 665–76CrossRef Google Scholar PubMed

DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M. & Holtzman, D. M. (2002). Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science, 295, 2264–7CrossRef Google Scholar

Farrer, M., Maraganore, D. M., Lockhart, P.et al. (2001a). Alpha-synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet., 10, 1847–51CrossRef Google Scholar

Farrer, M., Chan, P., Chen, R.et al. (2001b). Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol., 50(3), 293–300CrossRef Google Scholar

Fassbender, K., Simons, M., Bergmann, C.et al. (2001). Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci., USA, 98, 5856–61CrossRef Google Scholar PubMed

Gwinn-Hardy, K. (2002). Genetics of parkinsonism. Mov. Disord., 17(4), 645–56CrossRef Google Scholar PubMed

Haass, C. & Strooper, B. (1999). The presenilins in Alzheimer's disease – proteolysis holds the key. Science, 286, 916–19CrossRef Google Scholar PubMed

Hansen, L. A. & Samuel, W. (1997). Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology, 48(1), 126–32CrossRef Google Scholar PubMed

Hardy, J. & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297, 353–6CrossRef Google Scholar PubMed

Hardy, J. & Duff, K., Gwinn-Hardy, K., Pérez-Tur, J. & Hutton,, M. (1998). Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci., 1, 95–9Google Scholar PubMed

Hock, C., Konietzko, U., Streffer, J. R.et al. (2003). Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 38, 547–54CrossRef Google Scholar PubMed

Hosler, B. A., Siddique, T., Sapp, P. C.et al. (2000). Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21–q22. J. Am. Med. Assoc., 284(13), 1664–9CrossRef Google Scholar PubMed

Hutton, M., Lendon, C. L., Rizzu, P.et al. (1998). Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 393(6686), 702–5CrossRef Google Scholar PubMed

Irizarry, M. C., Soriano, F., McNamara, M.et al. (1997). Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci., 17, 7053–9CrossRef Google Scholar

Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. & Drachman, D. A. (2000). Statins and the risk of dementia. Lancet, 356, 1627–31CrossRef Google Scholar

Lewis, J., McGowan, E., Rockwood, J.et al. (2000). Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet., 25, 402–5CrossRef Google Scholar PubMed

Lewis, J., Dickson, D. W., Lin, W. L.et al. (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 293, 1487–91CrossRef Google Scholar PubMed

Lim, G. P., Yang, F., Chu, T.et al. (2001). Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Agin., 22, 983–91CrossRef Google Scholar PubMed

Masliah, E., Rockenstein, E., Veinbergs, I.et al. (2000). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science, 287, 1265–9CrossRef Google Scholar PubMed

Masliah, E., Rockenstein, E., Veinbergs, I.et al. (2001). Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl Acad. Sci. USA., 98, 12245–50CrossRef Google Scholar

Morgan, D., Diamond, D. M., Gottschall, P.et al. (2000). Vaccination with Aß peptide prevents memory deficits in an animal model of Alzheimer's disease. Nature, 408, 982–5CrossRef Google Scholar

Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H. & Weller, R. O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med., 9, 448–52CrossRef Google Scholar PubMed

Polymeropoulos, M. H., Lavedan, C., Leroy, E.et al. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045–7CrossRef Google Scholar PubMed

Refolo, L. M., Malester, B., LaFrancois, J.et al. (2000). Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis., 7, 321–31CrossRef Google Scholar

Refolo, L. M., Pappolla, M. A., LaFrancois, J.et al. (2001). A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis., 8(5), 890–9CrossRef Google Scholar

Rogers, J., Strohmeyer, R., Kovelowski, C. J. & Li, R. (2002). Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia, 40(2), 260–9CrossRef Google Scholar PubMed

Schenk, D., Barbour, R., Dunn, W.et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173–7CrossRef Google Scholar PubMed

Singleton, A. B., Farrer, M., Johnson, J.et al. (2003). α-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841CrossRef Google Scholar PubMed

Sparks, D. L., Martin, T. A., Gross, D. R. & Hunsaker, J. C. 3rd. (2000). Link between heart disease, cholesterol, and Alzheimer's disease: a review. Microsi. Res. Tech., 50, 287–903.0.CO;2-L>CrossRef Google Scholar PubMed

Sumpter, P. Q., Mann, D. M., Davies, C. A., Yates, P. O., Snowden, J. S. & Neary, D. (1986). An ultrastructural analysis of the effects of accumulation of neurofibrillary tangle in pyramidal neurons of the cerebral cortex in Alzheimer's disease. Neuropathol. Appl. Neurobiol., 12(3), 305–19CrossRef Google Scholar PubMed

Takashima, A., Honda, T., Yasutake, K.et al. (1998). Activation of tau protein kinase I/glycogen synthase kinase-3β by amyloid beta peptide (25–35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res., 31(4), 317–23CrossRef Google Scholar PubMed

Wahrle, S., Das, P., Nyborg, A. C.et al. (2002). Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis., 9, 11–23CrossRef Google Scholar PubMed

Weggen, S., Eriksen, J. L., Sagi, S. A.et al. (2003). Evidence that nonsteroidal anti-inflammatory drugs decrease Abeta 42 production by direct modulation of gamma – secretase activity. J. Biol. Chem., 278(34), 31831–7CrossRef Google Scholar

Weiner, H. L., Lemere, C. A., Maron, R.et al. (2000). Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol., 48, 567–793.0.CO;2-W>CrossRef Google Scholar

Winblad, B. & Blum, K. I. (2003). Hints of a therapeutic vaccine for Alzheimer's?Neuron, 38, 517–18CrossRef Google Scholar PubMed

Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G. & Siegel, G. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol., 57, 1439–43CrossRef Google Scholar PubMed